Q-omics provides the consensus-scored HBM profile across patient tissues and cancer cell-line models. HBM expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HBM is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, HBM protein abundance shows 11,290 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where HBM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HBM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HBM survival associations across molecular data types. HBM RNA expression shows survival associations in the most cancer types (15), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HBM RNA expression–survival associations across cancer types. High HBM expression shows unfavorable associations in BRCA, LUSC and READ, but favorable associations in KIRC, LIHC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HBM RNA expression.
This table summarizes HBM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HBM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HBM shows lower tumor expression in COAD, LUAD, LUSC, BRCA, THCA and UCEC. The COAD box plot shows higher HBM RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p < 0.001).
This table shows molecular features associated with HBM in patient tissues and cancer cell lines. In patient samples, HBM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HBM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
